In this week's FiercePharmaAsia wrap-up, Takeda has offered $5.2 billion to buy Ariad and made a $125 deal with Maverick on T-cell therapy R&D,…

An appeals court ruled against generics challenger Teva, potentially protecting Eli Lilly's cancer med Alimta until 2022.

Mylan is taking another hit tied to its EpiPen pricing controversy.

Allergan CEO Brent Saunders is tired of hearing from investors that chin-fat buster Kybella’s launch isn’t going as well as those of his company's other…

AbbVie joined the 10% price-hike pledge Wednesday, following Allergan and Novo Nordisk, as the drug pricing debate sent biopharma shares reeling once again.…

In the first complete response letter of the year, the FDA has asked Boston-area biotech Tesaro for more information about manufacturing by its two contractors…

On New Year’s Day, Sanofi and Boehringer Ingelheim closed a $12.5 billion asset swap that had been in the works for a year, giving the closely held Germany-…

Two months after U.S. lawmakers called for an investigation into the insulin market, Novo Nordisk faces a potential class-action lawsuit for its role in…

The J.P. Morgan Healthcare Conference is starting to wind down in San Francisco, but that doesn't mean the news has diminished.

Pharma